Nyaditum Resae® as a Co-adjuvant During Treatment for Active Pulmonary Tuberculosis and Its Impact on the Gut Microbiota

Tuberculosis Clinical Trial

Official title:

Nyaditum Resae® (a Food Supplement) as a Co-adjuvant During First-line Treatment for Active Pulmonary Tuberculosis and Its Impact on the Gut Microbiota - a Pilot Double-blind Randomised Controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03851159
• Other study ID #: N14_10_136
• Status: Recruiting
• Phase: N/A
• Start date: May 10, 2019
• Est. completion date: December 31, 2024

Study information

• Verified date: March 2024
• Source: University of Stellenbosch
• Contact: Grant Theron, PhD
• Phone: (+27) 21 938 9693
• Email: gtheron[@]sun.ac.za
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This will be the first study to evaluate the use of Nyaditum resae® as a potential agent for reducing antibiotic-associated gut dysbiosis in patients with drug-susceptible TB, and potentially improving clinical and microbiological markers of outcome

Description:

About one tenth of the 1.7 billion individuals infected with Mycobacterium tuberculosis (Mtb) will progress to active tuberculosis (TB). This probability increases in people with human immunodeficiency virus (HIV) and other risk co-morbidities such as malnutrition, diabetes and substance abuse. Chronic microbial colonisation with unrelated bacteria are associated with TB pathogenesis (e.g., mice colonised with Helicobacter hepaticus exhibit poor control of TB), indicating that the gut microbiota may modulate progression to active TB. Furthermore, first-line TB treatment (Isoniazid, Rifampicin, Ethambutol, Pyrazinamide; HREZ) depletes gut commensal bacteria (Ruminococcus, Coprococcus and Bifidobacterium) with immunomodulatory roles [interleukin (IL)-1, interferon (IFN)-γ and Th17 responses, respectively).

Recent work identified heat-killed Mycobacterium manresensis (hkMm), a harmless member of the fortuitum complex naturally found in drinking water, as a promising candidate for reducing the risk of active TB. Mtb-infected mice treated with hkMm had significantly reduced lung pathology (fewer and smaller lesions,) bacillary load and proinflammatory cytokines (TNF-α, IFN-γ, IL-6, and IL-17) compared to untreated control mice, and in mice receiving hkMm with HREZ, survival rates were significantly increased. Moreover, mice treated with hkMm had increased microbial diversity and an altered gut microbial composition relative to untreated mice. This could prove beneficial for TB patients during prolonged antibiotic treatment as supplementation with hkMm may help protect gut microbiota, and potentially improve clinical outcome.

In individuals with and without latent M. tuberculosis infection, two weeks of daily oral doses of Nyaditum resae® (a preparation of hkMm approved as a food supplement by Manremyc) demonstrated enhanced effector and memory specific regulatory T-cell responses. Similar clinical trials with Nyaditum resae® are currently being done in paediatrics (NCT02581579) and close contacts of active TB cases in Tbilisi, Georgia (NCT02897180; 2017-2023). The probiotic is also being registered as a food supplement in several countries.

In the proposed study, the efficacy of Nyaditum resae® in reducing antibiotic-associated gut dysbiosis and disease progression in patients with active TB will be tested. To do this, the investigators will assess changes in the microbiota during treatment (with or without Nyaditum resae® supplementation) and attempt to identify genera associated with a favourable or unfavourable treatment outcome in TB patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 48
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• 18-65 years

• New cases

• Sputum Xpert Ultra (Xpert) positive for Mycobacterium tuberculosis

• Have not initiated TB treatment

• If HIV-positive, are stable on antiretroviral therapy

Exclusion Criteria:

• Resistance to any of the first-line drugs (Xpert rifampicin-resistant)

• Previous TB

• Diabetes mellitus

• Taking immunomodulatory drugs (e.g. cancer chemotherapy, tumour necrosis factor (TNF) inhibitors or other anti-inflammatory medication, phosphodiesterase inhibitors, corticosteroids within the past 6 months, and cholesterol-lowering drugs)

• Pregnant or lactating women

• Chronic hepatitis

Related Conditions & MeSH terms

• Tuberculosis
• Tuberculosis, Pulmonary

Intervention

Dietary Supplement:
• Nyaditum resae®
Heat-killed Mycobacterium manresensis

Other:
• Mannitol
Placebo

Locations

Country	Name	City	State
South Africa	Scottsdene Clinic	Cape Town	Western Cape
South Africa	Wallacedene Clinic	Cape Town	Western Cape

Sponsors (2)

Lead Sponsor	Collaborator
University of Stellenbosch	Fundació Institut Germans Trias i Pujol

Country where clinical trial is conducted

South Africa, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Gut microbiome composition in placebo versus experimental arm	Gut microbial composition determined by next-generation sequencing of bacterial DNA in stool	Up to 18 months
Secondary	Cytokine and cluster of differentiation (CD)4+ T-cell response in placebo versus experimental arm	Cytokines responses profiled using commercial human cytokine panel, and T-cell responses characterised by flow cytometry on isolated peripheral blood mononuclear cells	Up to 18 months
Secondary	Time to sputum conversion and reduction in bacillary load	Culture used to assess sputum conversion and bacillary load	Up to 6 months